to do 
1. meet aarya to discuss approach 
2

to ask aarya 
For the cross-attention validation, do you want our attention weights to verify against the specific metabolic pathway enzymes documented in PharmGKB, or are we auditing the attention layers against a different set of protein targets?"

also - 
the two approaches- 30k to 4k discuss that 
2. GITHUB REPOS , 645 DRUGS, HOW MANY INTERACTIONS, SIMILAR TO DECAGON 14K 
how do i share data on discord/ github 

To ensure our benchmark results are directly comparable to the baseline Decagon paper (Zitnik et al., 2018), we are adopting the standard 645-drug, 963 side-effect split.

are we specifying which side effect is ther e
get exact number for metabolites 

meet?
how to decide metabolites 


biweekly- mention that drugbank features that led u to trust this approach would work- why mapping metabolites is hard and no other source is able to do this 

to do:
search uni/ manual google for metabolite sources - done 
one metabolite not the other- still works - ask mentors - dont 
also- discuss the mini project - research on that 

check intende- and get number 
consolidate all research 
build mindmap 
c2 go over try to maximise before tomorrow 


meet pointers 
1. how am i choosing primary metabolite 
2. if drugbank data were to come - wil we use and at what stage 
3. intende has the enzyme mapping and proper metabolite- 4k - but no available downloads for now- i emailed both prof 
4. discuss if we wanna keep this change of pitch - if metabolite 5k structures actually work out to be around 3k
5.. instead we use twosides extended database 
6. are we specifying which side effect is ther e
7. 
we should really start looking into how much of aaryas original approach will actually be abel=le to build in this time 
8. do i first batch on 645 or get that 3k set 
9.  Where exactly the gate acts — this is the one design choice to get right. Two options:

(a) Additive/concatenation gating: drug_repr = parent_vec + gate * metab_contribution, where metab_contribution comes from a small learned projection of metab_vec. Clean, easy to ablate, easy to explain.- simple and more interpretable. 
choice a 
Here, metabolite info is baked into each drug's single vector before pairing. There is no separate metabolite-to-metabolite attention map — it's implicitly mixed in. Simple, cheap, but you lose the ability to specifically say "the model attended atom X in Metabolite A to atom Y in Parent B."

(b) Gated cross-attention: metabolite vector participates as an extra key/value in the cross-attention fusion between Drug A and Drug B, but the attention weights into it are forced to zero (or the metab K/V rows are masked out) when gate=0.- ASK THIS 
metabolite in cross attention - 

choice b 
- in choice a-  the metabolite info gets blended into the drug's single vector before cross-attention starts, so by the time attention runs, we cant flag exact atoms. In the choice b- gated cross-attention version, the metabolite stays as its own separate set of keys/valuesalong with the parent's keys/values in the same attention step. The gate then just zeroes out that metabolite row when the drug doesn't have one, so it contributes nothing without needing a totally different code path.

practically- 
1. For each drug instead of producing one vector- we use two sets of Key/Value vectors- one for parent and one for mwtabolite atoms
2. stack them together into one combined K/V
3. multiply metabolite rows by gate (0 or 1)- before attention applied, so that if ) then attention assigns no real info. 
4. run cross attention normally- drug A's atoms over entire combined drug B table- and vice versa 
5. the attention weights themselves can be interpretability too- we can see which weights for metabolite vs parent drug. 





How you actually prove metabolites help — the ablation, concretely
This is the part that answers "will we compute cross-attention for parent-only separately and compare" — yes, exactly that, and here's how to do it without training two separate models:
Train one model, with the gate live during training (gate = actual has_metabolite flag, so the model learns to use metabolite info when available). Then at evaluation time, run the same trained model twice on the metabolite-complete pairs:
Pass 1 (real):        gate_A = 1, gate_B = 1  →  drug_repr uses real metabolite  →  AUROC_with_metab
Pass 2 (counterfactual): gate_A = 0, gate_B = 0  →  drug_repr = parent_vec only    →  AUROC_without_metab
Same weights, same trained model, only the gate is forced off in pass 2. This isolates the causal contribution of metabolite information, because everything else (learned weights, biological branch, fusion) is identical between the two passes. If AUROC_with_metab > AUROC_without_metab on the same pairs, that's a clean, defensible result — you're not comparing two differently-trained models or two different subsets, you're comparing the same model with a feature switched on vs off on the same test examples.

This is a stronger design than what I implied before (comparing metabolite-complete vs. metabolite-incomplete pairs, which conflates "this pair had metabolite data" with "other pairs are just different pairs"). The forced-gate-off counterfactual is the version that actually isolates metabolite contribution as a variable, holding the pair and the model fixed. I'd lead with this in your results section — it's the real "does metabolite-awareness help" experiment, and the metabolite-complete-vs-incomplete comparison becomes a secondary, supporting analysis (useful for showing real-world data-availability tradeoffs, but not your main causal claim).
One thing to decide: should the gate be trainable/stochastic during training (e.g., randomly drop metabolite info for some metabolite-complete pairs during training, like dropout) so the model doesn't become overly dependent on always having it, which would make the forced-off counterfactual unfairly bad? I'd suggest yes — apply gate-dropout (e.g., randomly zero the metabolite pathway 20-30% of the time during training even when data exists) so the parent-only pathway stays well-trained and the counterfactual comparison is fair rather than crippled.



The direct answer: an updated, larger TwoSIDES already exists
The Decagon-standard 645-drug/63,473-pair set you've been using is actually a filtered subset of the original 2012 Tatonetti TWOSIDES data, curated down for statistical reliability (minimum 500-pair support per side-effect type). But the Tatonetti Lab has since updated and expanded this: nSIDES, the current home for their drug side-effect and interaction resources, now hosts a TwoSIDES covering over 3,300 drugs and roughly 63,000 combinations — about 5x more unique drugs while keeping a similar total pair count to what you're used to. It's the same lineage/methodology as the Decagon-era data, just refreshed and broadened, and it's freely downloadable at nsides.io.
This is very likely your answer: swap your parent-drug pool from the narrow 645-drug Decagon cut to this larger ~3,300-drug nSIDES version. You stay within the same well-established dataset family (so you can still cite/compare against Decagon-style baselines credibly), but you get 5x the chemical diversity to intersect against INTEDE (4,701 drugs) and LAGOM (5,322 compounds) — which directly attacks the exact problem we flagged earlier: thin metabolite-complete pair counts.

10. if this also doesnt work- should i thin kabout biotransformer or js leave metabolite
11. How you actually prove metabolites help — the ablation, concretely
This is the part that answers "will we compute cross-attention for parent-only separately and compare" — yes, exactly that, and here's how to do it without training two separate models:
Train one model, with the gate live during training (gate = actual has_metabolite flag, so the model learns to use metabolite info when available). Then at evaluation time, run the same trained model twice on the metabolite-complete pairs:
Pass 1 (real):        gate_A = 1, gate_B = 1  →  drug_repr uses real metabolite  →  AUROC_with_metab
Pass 2 (counterfactual): gate_A = 0, gate_B = 0  →  drug_repr = parent_vec only    →  AUROC_without_metab
12. now hosts a TwoSIDES covering over 3,300 drugs and roughly 63,000 combination
13. Lagom
Per the paper's own description, expect columns roughly corresponding to: parent SMILES, metabolite SMILES, and likely some identifier/name field. Important curation details already baked in (useful to know so you don't reapply them redundantly): compounds are restricted to specific elements (C, O, N, Cl, F, S, P, Br, I), and parent-metabolite pairs are filtered by Tanimoto similarity > 0.2 (1024-bit Morgan fingerprints) to exclude spurious/unrelated pairings.

14. Whether "only one drug in the pair has a metabolite" should count toward the main metabolite-aware result, or only be reported separately

workflow:

1. Path 1: clone repo, env setup, run 0_get_dataset.py - 2-4h 
2. Get PubChem SMILES + InChIKeys for your 645 drugs (batch API pull)- 1-2h 
3. cimopute inchikeys for lagom smiles using rdkit - 30/60 min
4.Merge/match on InChIKey (full + 14-char skeleton fallback)
5. Fuzzy name-matching for stragglers + manual spot-check of matches
6. debug ai code: 8-15h 

67k pairs - agted approach 


keep in mind 
don't wait for InChIKey matching to be perfect before you get your coverage number. Run the full pipeline once, even sloppily, get a number for % of 645 drugs matched, and only invest more time in the fuzzy-matching/spot-check refinement if that number is borderline 